Article

Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast Cancer

2026-07-13

Abstract excerpt

<h4>Purpose</h4> Exceptional responses are frequent in patients with HER2-positive (HER2+) metastatic breast cancer (MBC), but predictive biomarkers are lacking. We aimed to investigate the association between detection of minimal residual disease (MRD) via circulating tumor DNA (ctDNA) and exceptional response to first-line HER2 targeted therapy for MBC. <h4>Patients and Methods</h4> We identified exceptional (...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bcd9ef47-5dfe-5a88-8661-dacc51d79a60
DOI: 10.64898/2026.07.09.26357137

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast CancerDOI 10.64898/2026.07.09.26357137Read

Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancerSemantic proximity Read

Detection of residual disease after neoadjuvant therapy in breast cancer using personalized circulating tumor DNA analysisSemantic proximity Read

Whole genome sequencing-powered ctDNA sequencing for breast cancer detectionSemantic proximity Read

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Semantic proximity Read

Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast CancerSemantic proximity Read

Genomic landscape of extraordinary responses in metastatic breast cancer.Semantic proximity Read

Revolutionizing Detection of Minimal Residual Disease in Breast Cancer Using Patient-Derived Gene SignatureSemantic proximity Read

Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assaySemantic proximity Read

OncoMRD BREAST for Monitoring Minimal Residual Disease in Breast Cancer: A Megadata Large-Scale Retrospective Clinical Correlation StudySemantic proximity Read

Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient ManagementSemantic proximity Read

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Semantic proximity Read

MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies.Semantic proximity Read